DANAHER CORPORATION's ticker is DHR and the CUSIP is 235851102. A total of 2,042 filers reported holding DANAHER CORPORATION in Q3 2023. The put-call ratio across all filers is 0.89 and the average weighting 0.6%.
About DANAHER CORPORATION
Danaher Corporation is a global science and technology company that designs, manufactures, and markets innovative products and services to professional, medical, industrial, and commercial customers. The company operates through four segments: Life Sciences, Diagnostics, Dental, and Environmental & Applied Solutions.
Danaher's Life Sciences segment provides a range of research tools to scientists around the world, including mass spectrometry, chromatography, and automation systems. The Diagnostics segment offers a broad range of diagnostic products, including clinical chemistry, immunoassay, microbiology, and molecular diagnostic systems. The Dental segment provides a range of dental equipment and consumables, including imaging systems, dental instruments, and consumables. The Environmental & Applied Solutions segment offers a range of products and services to help customers protect the environment and improve productivity.
Danaher has a strong track record of growth and innovation, driven by its focus on continuous improvement and customer satisfaction. The company has a culture of operational excellence, which has enabled it to consistently deliver high-quality products and services to its customers. Danaher's management team is highly experienced and has a proven track record of creating value for shareholders.
In conclusion, Danaher Corporation is a well-established and innovative company that is well-positioned to continue delivering strong growth and value to its shareholders. With its focus on operational excellence and customer satisfaction, Danaher is a company that investors should keep an eye on.
It's important to note that this information is for educational purposes only and has not been fact-checked. As with any investment, it's important to do your own research and consult with a financial advisor before making any investment decisions.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $559,393,055 | -6.8% | 2,254,708 | -9.9% | 0.44% | +7.6% |
| Q2 2023 | $600,385,920 | -13.2% | 2,501,608 | -8.9% | 0.41% | -13.9% |
| Q1 2023 | $691,725,796 | -7.2% | 2,744,508 | -2.3% | 0.47% | -11.4% |
| Q4 2022 | $745,487,277 | -3.6% | 2,808,708 | -6.2% | 0.54% | -3.3% |
| Q3 2022 | $773,132,000 | +3.4% | 2,993,270 | +1.5% | 0.55% | +9.3% |
| Q2 2022 | $747,369,000 | -8.5% | 2,947,970 | +5.8% | 0.51% | +9.8% |
| Q1 2022 | $817,091,000 | +1.7% | 2,785,570 | +14.1% | 0.46% | -4.8% |
| Q4 2021 | $803,465,000 | +4.0% | 2,442,070 | -3.8% | 0.48% | -1.4% |
| Q3 2021 | $772,751,000 | +10.2% | 2,538,270 | -2.9% | 0.49% | +13.4% |
| Q2 2021 | $701,404,000 | +11.2% | 2,613,670 | -6.7% | 0.43% | +3.1% |
| Q1 2021 | $630,544,000 | +3.2% | 2,801,420 | +1.9% | 0.42% | -3.2% |
| Q4 2020 | $610,867,000 | +0.8% | 2,749,920 | -2.3% | 0.43% | -8.4% |
| Q3 2020 | $605,835,000 | +21.9% | 2,813,520 | +0.1% | 0.47% | +12.9% |
| Q2 2020 | $496,860,000 | +29.2% | 2,809,820 | +1.1% | 0.42% | +2.9% |
| Q1 2020 | $384,630,000 | +9.4% | 2,778,920 | +21.3% | 0.41% | +13.0% |
| Q4 2019 | $351,610,000 | -0.4% | 2,290,920 | -6.2% | 0.36% | -3.7% |
| Q3 2019 | $352,902,000 | +2.0% | 2,443,412 | +1.0% | 0.38% | +0.5% |
| Q2 2019 | $345,844,000 | +3.4% | 2,419,844 | -4.5% | 0.37% | +1.6% |
| Q1 2019 | $334,386,000 | +31.7% | 2,532,844 | +2.9% | 0.37% | +12.6% |
| Q4 2018 | $253,938,000 | -3.9% | 2,462,544 | +1.3% | 0.33% | +10.9% |
| Q3 2018 | $264,190,000 | +6.5% | 2,431,344 | -3.2% | 0.29% | +3.5% |
| Q2 2018 | $247,967,000 | +3.7% | 2,512,844 | +2.9% | 0.28% | -2.7% |
| Q1 2018 | $239,179,000 | -4.1% | 2,442,844 | -9.1% | 0.29% | +8.6% |
| Q4 2017 | $249,504,000 | +8.9% | 2,688,044 | +0.7% | 0.27% | +3.1% |
| Q3 2017 | $229,079,000 | +2.6% | 2,670,544 | +1.0% | 0.26% | -1.5% |
| Q2 2017 | $223,182,000 | +1.6% | 2,644,644 | +2.9% | 0.26% | -2.9% |
| Q1 2017 | $219,739,000 | +36.2% | 2,569,144 | +24.0% | 0.27% | +7.5% |
| Q4 2016 | $161,303,000 | +19.9% | 2,072,244 | +20.7% | 0.25% | +17.6% |
| Q3 2016 | $134,544,000 | -23.2% | 1,716,344 | -1.0% | 0.22% | -23.7% |
| Q2 2016 | $175,088,000 | +20.2% | 1,733,544 | +8.2% | 0.28% | +6.0% |
| Q1 2016 | $145,675,000 | +40.4% | 1,602,344 | +43.4% | 0.27% | +6.4% |
| Q4 2015 | $103,788,000 | +11.3% | 1,117,444 | +2.1% | 0.25% | +5.0% |
| Q3 2015 | $93,275,000 | +6.4% | 1,094,644 | +6.9% | 0.24% | +5.3% |
| Q2 2015 | $87,682,000 | +7.2% | 1,024,444 | +6.3% | 0.23% | +4.1% |
| Q1 2015 | $81,796,000 | +62.8% | 963,444 | +64.3% | 0.22% | +16.0% |
| Q4 2014 | $50,256,000 | +9.6% | 586,344 | -2.8% | 0.19% | +6.8% |
| Q3 2014 | $45,834,000 | -5.0% | 603,244 | -1.5% | 0.18% | -1.1% |
| Q2 2014 | $48,233,000 | +12.0% | 612,644 | +6.6% | 0.18% | +5.3% |
| Q1 2014 | $43,083,000 | -11.4% | 574,444 | -8.8% | 0.17% | -11.1% |
| Q4 2013 | $48,639,000 | +7.4% | 630,044 | -3.6% | 0.19% | +0.5% |
| Q3 2013 | $45,283,000 | +14.6% | 653,244 | +4.6% | 0.19% | +8.6% |
| Q2 2013 | $39,521,000 | – | 624,344 | – | 0.17% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ARTHUR M. COHEN & ASSOCIATES, LLC | 217,436 | $53,823,432 | 13.80% |
| Defender Capital, LLC. | 152,962 | $37,949,802 | 13.74% |
| Bancreek Capital Management, LP | 60,890 | $15,106,809 | 13.58% |
| BOONE CAPITAL MANAGEMENT LLC | 129,163 | $32,045,340 | 10.11% |
| Eagle Health Investments LP | 175,085 | $43,438,589 | 9.57% |
| Third Point | 2,450,000 | $607,845,000 | 9.22% |
| Clio Asset Management LLC | 41,695 | $10,344,530 | 9.04% |
| Consulta Ltd | 500,000 | $124,050,000 | 8.91% |
| Riverstone Advisors, LLC | 47,960 | $11,799,701 | 8.16% |
| CADEN CAPITAL PARTNERS, LP | 123,755 | $27,215,377 | 7.66% |